NEKTAR THERAPEUTICS - 10-Q Filing
Nektar Therapeutics filed its quarterly report on Form 10-Q for the quarter ended March 31, 2026. The filing includes details about restructuring costs and asset impairment charges, as well as financial data related to equity investments such as Gannet BioChem. It also references agreements including purchase and sale agreements from prior years and outlines subsequent events like an underwritten offering scheduled for April 23, 2026.
Tickers: $NKTR